摘要
目的:探讨肠道益生菌辅助治疗对非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)患者红细胞分布宽度与血小板计数比值(RPR)及肝纤维化的影响。方法:选取2018年1月至2019年3月上海市长宁区天山社区卫生服务中心收治的NAFLD患者130例,按照随机数字表法分为研究组和对照组,每组65例。对照组患者给予NAFLD常规治疗,研究组患者在对照组的基础上加用双歧杆菌三联活菌胶囊。比较两组患者干预前后RPR、体重指数(BMI)及肝纤维化指标[血清透明质酸(HA)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C)及层粘连蛋白(LN)]水平的差异。结果:干预后,两组患者RPR、BMI水平均较干预前有所降低;且研究组患者RPR、BMI水平明显低于对照组,差异有统计学意义(P<0.05)。干预后,两组患者HA、PC-Ⅲ、Ⅳ-C及LN水平较干预前明显降低,且研究组患者明显低于对照组,差异均有统计学意义(P<0.05)。结论:肠道益生菌辅助治疗NAFLD可有效降低患者RPR、BMI以及肝纤维化指标水平,有利于控制病情进展。
OBJECTIVE:To probe into the effects of intestinal probiotics adjuvant therapy on red blood cell distribution width/platelet count(RPR)index and liver fibrosis in patients with nonalcoholic fatty liver disease(NAFLD).METHODS:Totally 130 patients with NAFLD admitted into Shanghai Changning District Tianshan Road Community Health Service Center from Jan.2018 to Mar.2019 were extracted to be divided into the study group and the control group via the random number table,with 65 cases in each group.The control group was given NAFLD conventional treatment,while the study group additionally received Bifidobacterium triple viable capsule on the basis of the control group.Differences of RPR,body mass index(BMI)and liver fibrosis index[serum hyaluronic acid(HA),procollagen typeⅢ(PC-Ⅲ),collagen typeⅣ(Ⅳ-C),laminin(LN)]levels of two groups were compared before and after intervention.RESULTS:After intervention,the levels of RPR and BMI in both groups were lower than those before intervention,moreover,the levels of RPR and BMI of the study group were significantly lower than those of the control group,with statistically significant differences(P<0.05).After intervention,the levels of HA,PC-Ⅲ,Ⅳ-C and LN in two groups were significantly lower than those before intervention,and the study group was significantly lower than the control group,with statistically significant differences(P<0.05).CONCLUSIONS:Intestinal probiotics in the adjuvant therapy of NAFLD can effectively reduce the levels of RPR,BMI and liver fibrosis indicators in patients,which is conducive to the control of disease progression.
作者
周灿灿
杨文卓
ZHOU Cancan;YANG Wenzhuo(Medical College of Tongji University, Shanghai 200092, China;Dept. of General Medicine, Shanghai Tianshan Road Community Health Service Center, Shanghai 200051, China;Dept. of Gastroenterology, Tongji Hospital Affiliated to Shanghai Tongji University, Shanghai 200065, China)
出处
《中国医院用药评价与分析》
2020年第3期297-299,303,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
